U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C30H34N8
Molecular Weight 506.6457
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BEMCENTINIB

SMILES

c1ccc-2c(c1)CCCc3cc(nnc32)-n4c(=N)nc(Nc5ccc6CC[C@@]([H])(CCc6c5)N7CCCC7)[nH]4

InChI

InChIKey=KXMZDGSRSGHMMK-VWLOTQADSA-N
InChI=1S/C30H34N8/c31-29-33-30(32-24-13-10-20-11-14-25(15-12-22(20)18-24)37-16-3-4-17-37)36-38(29)27-19-23-8-5-7-21-6-1-2-9-26(21)28(23)35-34-27/h1-2,6,9-10,13,18-19,25H,3-5,7-8,11-12,14-17H2,(H3,31,32,33,36)/t25-/m0/s1

HIDE SMILES / InChI

Molecular Formula C30H34N8
Molecular Weight 506.6457
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT02424617 | https://clinicaltrials.gov/ct2/show/NCT02872259 | http://www.rigel.com/index.php/about-rigel/current-partners/bergenbio/

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM. R428 was originated in Rigel Pharmaceuticals and was licensed to BerGenBio, which initiated clinical trials for the treatment of non-small cell lung cancer, metastatic melanoma and acute myeloid leukaemia.

Originator

Curator's Comment:: R428 was licensed to BerGenBio, where it is being developed under name of BGB324 http://www.rigel.com/index.php/about-rigel/current-partners/bergenbio/

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
14.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
2010 Feb 15
Patents

Sample Use Guides

For treatment of metastatic melanoma R428 (BGB324) is administered in capsules, 400 mg once daily for 3 days, followed by 200 mg once daily pembrolizumab 2 mg/kg IV every 3
Route of Administration: Oral
A five-point R428 dose titration was performed in radiometric in vitro kinase assays on 133 kinases at the KmATP for each kinase (Millipore). Axl, Mer, and Tyro3 (Carna Biosciences) assays were also performed using a fluorescence polarization protocol.
Substance Class Chemical
Created
by admin
on Sat Jun 26 09:15:20 UTC 2021
Edited
by admin
on Sat Jun 26 09:15:20 UTC 2021
Record UNII
0ICW2LX8AS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BEMCENTINIB
USAN   INN  
Official Name English
BEMCENTINIB [WHO-DD]
Common Name English
R-428
Code English
1H-1,2,4-TRIAZOLE-3,5-DIAMINE, 1-(6,7-DIHYDRO-5H-BENZO(6,7)CYCLOHEPTA(1,2-C)PYRIDAZIN-3-YL)-N3-((7S)-6,7,8,9-TETRAHYDRO-7-(1-PYRROLIDINYL)-5H-BENZOCYCLOHEPTEN-2-YL)-
Systematic Name English
BEMCENTINIB [USAN]
USAN  
Common Name English
BEMCENTINIB [INN]
Common Name English
W-5845
Code English
1-(6,7-DIHYDRO-5H-BENZO(6,7)CYCLOHEPTA(1,2-C)PYRIDAZIN-3-YL)-N3-((7S)-7-(PYRROLIDIN-1-YL)-6,7,8,9-TETRAHYDRO-5H-BENZO(7)ANNULEN-2-YL)-1H-1,2,4-TRIAZOLE-3,5-DIAMINE
Systematic Name English
BGB-324
Code English
KB-80319
Code English
QC-11751
Code English
HY-15150
Code English
CS-1046
Code English
R428
Code English
BGB324
Code English
SYN-1131
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 452314
Created by admin on Sat Jun 26 09:15:20 UTC 2021 , Edited by admin on Sat Jun 26 09:15:20 UTC 2021
Code System Code Type Description
PUBCHEM
46215462
Created by admin on Sat Jun 26 09:15:20 UTC 2021 , Edited by admin on Sat Jun 26 09:15:20 UTC 2021
PRIMARY
ChEMBL
CHEMBL2023349
Created by admin on Sat Jun 26 09:15:20 UTC 2021 , Edited by admin on Sat Jun 26 09:15:20 UTC 2021
PRIMARY
FDA UNII
0ICW2LX8AS
Created by admin on Sat Jun 26 09:15:20 UTC 2021 , Edited by admin on Sat Jun 26 09:15:20 UTC 2021
PRIMARY
DRUG BANK
DB12411
Created by admin on Sat Jun 26 09:15:20 UTC 2021 , Edited by admin on Sat Jun 26 09:15:20 UTC 2021
PRIMARY
CAS
1037624-75-1
Created by admin on Sat Jun 26 09:15:20 UTC 2021 , Edited by admin on Sat Jun 26 09:15:20 UTC 2021
PRIMARY
EPA CompTox
1037624-75-1
Created by admin on Sat Jun 26 09:15:20 UTC 2021 , Edited by admin on Sat Jun 26 09:15:20 UTC 2021
PRIMARY
INN
10631
Created by admin on Sat Jun 26 09:15:20 UTC 2021 , Edited by admin on Sat Jun 26 09:15:20 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY